News & Updates
Filter by Specialty:
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
19 Jun 2023Family-based treatment helps with weight loss in children with overweight, obesity
The implementation of family-based treatment for overweight or obesity in paediatric primary care settings has demonstrated success, with a recent study showing that the treatment led to improved weight outcomes.
Family-based treatment helps with weight loss in children with overweight, obesity
17 Jun 2023Add-on myoinositol helps with menstrual period regularity in women with PCOS
In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.
Add-on myoinositol helps with menstrual period regularity in women with PCOS
12 Jun 2023NAFLD a risk factor for young-onset hypertension
Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.
NAFLD a risk factor for young-onset hypertension
09 Jun 2023Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
09 Jun 2023T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.